Literature DB >> 9404765

Penicillin dosing for pneumococcal pneumonia.

C S Bryan1, R Talwani, M S Stinson.   

Abstract

Most textbook authors still endorse penicillin G as the specific antibiotic of choice for pneumococcal pneumonia. However, problems with early precise etiologic diagnosis of pneumonia and the emergence of drug-resistant pneumococci cause penicillin to be seldom used for this purpose today. A third explanation for the infrequent use of penicillin is lack of clear consensus dosing guidelines. Emergence of pneumococci resistant to the newer cephalosporins and concerns about overuse of vancomycin, however, have prompted renewed interest in the development of precise, rapid methods for diagnosis of pneumococcal pneumonia with the implication that penicillin might be used more frequently. We review several issues concerning penicillin dosing: intermittent vs continuous therapy, high dose vs low dose, relationship of dose to resistance, and cost-effective pharmacology. An optimum "high-dose" regimen for life-threatening pneumococcal pneumonia in a 70-kg adult consists of a 3 million unit (mu) loading dose followed by continuous infusion of 10 to 12 mu of freshly prepared drug every 12 h. The maintenance dose should be reduced in elderly patients and in patients with renal failure according to the following formula: dose (mu/24 h = 4+[creatinine clearance divided by 7]). This regimen provides a penicillin serum level of 16 to 20 microg/mL, which should suffice for all but the most highly resistant strains (minimum inhibitory concentration > or = 4 microg/mL). Newer cephalosporins and vancomycin can be reserved for patients with suspected meningitis or endocarditis or for localities in which highly resistant pneumococci are known to be prevalent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404765     DOI: 10.1378/chest.112.6.1657

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Ambulatory use of parenteral antibacterials: contemporary perspectives.

Authors:  J E Leggett
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 2.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Drug treatment of pneumococcal pneumonia in the elderly.

Authors:  Sridhar Neralla; Keith C Meyer
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Systematic review of the clinical outcomes of pneumonia with a penicillin-group resistant pneumococcus in respiratory and blood culture specimens in children in low- and middle-income countries.

Authors:  Maeve Hume-Nixon; Ruth Lim; Fiona Russell; Hamish Graham; Claire von Mollendorf; Kim Mulholland; Amanda Gwee
Journal:  J Glob Health       Date:  2022-08-22       Impact factor: 7.664

5.  Efficacy of high doses of oral penicillin versus amoxicillin in the treatment of adults with non-severe pneumonia attended in the community: study protocol for a randomised controlled trial.

Authors:  Carl Llor; Javier Arranz; Rosa Morros; Anna García-Sangenís; Helena Pera; Joan Llobera; Mireia Guillén-Solà; Eugenia Carandell; Jesús Ortega; Silvia Hernández; Marc Miravitlles
Journal:  BMC Fam Pract       Date:  2013-04-17       Impact factor: 2.497

6.  Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial.

Authors:  Carl Llor; Almudena Pérez; Eugenia Carandell; Anna García-Sangenís; Javier Rezola; Marian Llorente; Salvador Gestoso; Francesc Bobé; Miguel Román-Rodríguez; Josep M Cots; Silvia Hernández; Jordi Cortés; Marc Miravitlles; Rosa Morros
Journal:  Aten Primaria       Date:  2017-10-20       Impact factor: 1.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.